Key words Ewing's sarcoma, Multi-drug chemotherapy, Orbital, Primary, Proptosis, Radiotherapy Ewing's sarcoma is thought to be the least differentiated of a group of small cell neoplasms with various degrees of neuroectodermal differentiation.1 It most commonly arises in the diaphysis of a long bone, or in the ribs, pelvis or vertebrae? Primary orbital involvement or localisation is very rare. Since 1950, when Harbert and Tabor3 reported the first case of primary orbital Ewing's sarcoma, only 7 others have been reported (Table 1) .
A definitive cure of Ewing's sarcoma can be achieved only if all local and systemic cancer cells are eradicated? Tremendous progress in the treatment of Ewing's sarcoma has been made in the past 25 years. The development of multi-agent chemotherapy protocols has increased the 5 year survival rate of Ewing's sarcoma patients from 5-10% twenty years ago, to more than 70% now.4 Surgical resection of the primary tumour is still considered the treatment of choice for local control, but this often results in cosmetic mutilation and physical handicap. The efficacy of radiotherapy for local control is still under debate, even though these tumours are usually radiosensitive. For systemic control of non pelvic Ewing's sarcoma,s a high-dose multi drug chemotherapy regimen (adriamycin, cyclophosphamide, vincristine and actinomycin) has been shown to be effective in achieving a high rate of recurrence-free survival.
In our case we used a combination of multi drug chemotherapy and local radiotherapy, in accordance with the protocol of the 1992 European Intergroup Co-operative Ewing's Sarcoma (EICES) study.6 An encouraging result was achieved in that the patient has remained well, with no recurrence, for 30 months after completion of treatment.
Case report
A 2-year-old boy with a 1 month history of bilateral painless proptosis was referred to our institution for further investigation and management. The child had no prior medical problems and, more specifically, no history of thyrOid or renal disease. Family history was non-contributory and the boy was an only child.
Examination revealed bilateral proptosis. Visual acuity was hand movement and 20/50 in the right and left eyes, respectively. There was an afferent pupillary defect of the right eye. Fundus examination revealed no papilloedema. Both optic discs were pink and appeared normal. The range of extraocular movement was full, the cranial nerves were intact and no other neurological deficits were found.
The patient was admitted for further investigations. A complete blood count showed a normal level of haemoglobin (13.5 g/ dl), white cell count (9 X 109/1) and platelet count (342 X 109/1). Erythrocyte sedimentation rate was 36 mm/h. Liver function tests, electrolytes, urea and creatinine levels were all within normal limits. A computed tomography (CT) scan showed an enhancing soft tissue mass involving the medial orbits, the ethmoidal sinuses and the anterior cranial fossa (Fig. 1) . Tissue biopsy of the tumour was obtained through the nasal sinus, and standard as well as special immunohistochemical stains were used to identify the nature of the tumour.
Histological examination revealed the mass to be a small round cell tumour. Haematoxylin and eosin stain showed the presence of sheets of monotonous small round cells that infiltrated the lamina propria (Fig. 2 ).
These cells were positive for the periodic acid-Schiff (PAS) stain and the PAS staining was diastase sensitive.
Immunohistochemical stains showed focal positivity for neurone-specific enolase and diffuse positivity for the MIC2 marker (Fig. 3) . The MIC2 marker is used to detect MIC2 protein, whose production is controlled by the Radiotherapy was set to be started after the induction chemotherapy, but was delayed for a long time as his parents were afraid of its potential side effects.
Radiotherapy was ultimately started after completion of the entire 42 weeks of chemotherapy. Because we felt that the patient's parents might refuse radiotherapy, thus leaving chemotherapy as the only treatment, we added etoposide to the four drugs (i.e. therapy was changed from the V AlA to the EV AlA regimen) after the first ten courses.
When finally agreed to by the parents, the radiotherapy was delivered through a pair of left and right opposing portals; the radiation field was 5 X 7 cm, and included the initial tumour volume with its superior border placed at about 1.2 cm above the roof of the sphenoid sinus. Divergent blocks protected regions outside the treatment field. The total dose of radiation was 45 Gy, delivered in fractions of 1.8 Gy per day, 5 days a week. Radiation was completed in 5 weeks.
Subsequent follow-up CT scans (Fig. 4) showed no evidenc.e of residu.al tu.mour and onl y minimal reactive inflammatory fibrosis of the orbits. The patient's visual acuity improved to 20/80 and 20/40 in the right and left eyes respectively. At the time of writing he has been in remission for 30 months since the last dose of radiotherapy, and apart from very slight temporal disc pallor in both eyes, no radiation-induced cataract, keratitis, retinopathy, neuropathy, abnormal orbital growth or secondary malignant tumour has been observed.
Discussion
Primary Ewing's sarcoma rarely involves the orbit and, in fact, less than 5% of the cases of Ewing's sarcoma arise anywhere in the skull region? Since 1950, when the first case of Ewing's sarcoma of the orbit was described, only 7 other cases have been reported in the literature (Table  1) . Among reported cases there was male-to-female ratio of 6 to 2, with a tendency for involvement of the right orbit (right: left, 6:2). The mean age at presentation was 18 years (range 6-61 years), with most patients being diagnosed in late childhood or early adulthood. The two youngest cases reported previously, by Alvarez-Berdecia et al.8 and Woodruff et al} were both 6 years old. The oldest patient was a 61-year-old man reported by Yamada and Takahashi.lO Our case is the youngest of all the previously reported cases of primary orbital Ewing's sarcoma, being only 2 years old at the time of diagnosis. Moreover, of the 8 previously reported cases, no bilateral orbital involvement was reported, so this is the first case with bilateral orbital involvement. Furthermore, this is one of the cases with the most extensive involvement (both orbits, both ethmoidal sinuses and anterior cranial fossa), there being only 2 other cases with orbital, sinus and cranial fossa involvement.9 ,11
The most common presentation of primary orbital Ewing's sarcoma is proptosis, with or without pain, but other presenting symptoms include visual loss and headache. Major differential diagnoses for bilateral proptosis in a 2-year-old child include orbital trauma, infection, inflammation, dysthyroid eye disease, cavernous sinus disorder, and primary or secondary tumours. Primary tumours, such as rhabdomyosarcoma, optic glioma, lymphangioma and infiltrative lymphoma, although uncommon, have to be considered. Secondary tumours, such as mesenchymal cell chondrosarcoma, neuroblastoma and histiocytosis X, are also rare but possible causes.
Ewing's sarcoma is the least differentiated of a group of small round cell tumours that have various degrees of neuroectodermal differentiation. Other members of this group are peripheral neuroepitheliomas and neuroblastomasY Difficulty had been encountered in distinguishing Ewing's sarcoma from other small round cell tumours when they occur in the orbital region.5 ,1 2-1 4 Exact diagnostic criteria for distinguishing Ewing's sarcoma from peripheral neuroepithelioma have not been generally agreed upon. Histologically, both tumours consist of small round cells with scanty cytoplasm and fine chromatin; cytogenetically, both possess translocation abnormality t(1l,22). For rather general classification, tumours with Homer-Wright rosettes and definite positivity for more specific neural markers such as synoptophysin or neurofilament, or ultrastructural demonstration of dense core granules, are classified as peripheral neuroepitheliomas. Otherwise, both Ewing's sarcoma and malignant peripheral neurectodermal tumours react positively to the MIC2 marker and to neurone-specific enolose. 1 4 In the past 25 years marked progress has been made in the treatment of Ewing's sarcoma. The mainstay of treatment for Ewing's sarcoma is surgery for local removal of the tumour and chemotherapy for control of distant spread. 1 5 ,1 6 Chemotherapy has been very effective in eradicating subclinical distant metastastis, which would otherwise develop in an estimated 75-85% of cases within the first 2 years? This has increased the 5 year survival rate tremendously, from 5% in the past to more than 70% now? , 4 , 5 For local tumour control, surgery may not be the treatment of choice if its mutilating effect is expected to be substantial. Radiotherapy is an alternative, but may not be as effective as surgery. For systemic control, a clinical trial of multi-drug chemotherapy has shown this treatment to be useful in improving the relapse-free survival to 73% at a median follow-up of 5.6 years. 1 7 The chemotherapy regimen first studied consisted of high-dose V AlA, begun 2-4 weeks after histological diagnosis. In 1990, a group of German investigators suggested intensive chemotherapy with V AlA followed by either surgery, radiotherapy or both. 1 6 This protocol was further consolidated into the new EleES (1992) study protocol. 6 Among the 8 previously reported cases, surgical excision was performed in 5. 8 ,10,11,1 8 ,1 9 Surgical biopsy was performed on 2 of the patients, who were later treated successfully by combined radiotherapy and chemotherapy without further surgery.9 ,1 9 In our patient, because the tumour involvement was very extensive, surgical debulking would have resulted in much mutilation and de-functioning, so high-dose radiation therapy was used for local control. Radiotherapy, however, is not without risk. Numerous complications, including radiation cataract, retinopathy, abnormal orbital growth and secondary tumours, can occur.2 0, 2 1 Although no such complications have been noted in our patient at the time of writing, close observation is essential. Overall, the results have been very encouraging in that this child has remained in remission for 30 months after completion of treatment, and has enjoyed good functional and cosmetic outcome.
